Real-world clinical results of CGRP monoclonal antibody treatment for medication overuse headache of migraine without abrupt drug discontinuation and no hospitalization
When CGRP-mAb was administered to migraine with MOH, frequency of headache symptoms and AMU were reduced without abrupt drug discontinuation and no hospitalization.
Authors
- Miki Hashida (ORCID: https://orcid.org/0009-0000-6930-4078)
- Manabu Mutoh (ORCID: https://orcid.org/0009-0002-4778-5135)
- Yoshiki Ito (ORCID: https://orcid.org/0009-0006-0909-2353)
- Ryuta Saito (ORCID: https://orcid.org/0000-0002-2484-1360)
- Satoshi Maesawa (ORCID: https://orcid.org/0000-0001-7518-0171)
- Yutaro Fuse (ORCID: https://orcid.org/0000-0001-9402-8079)
- Takafumi Tanei (ORCID: https://orcid.org/0000-0002-9251-4230)
- Toshihiko Wakabayashi
- Yoshitaka Nagashima (ORCID: https://orcid.org/0000-0001-9346-1663)
- Tomotaka Ishizaki (ORCID: https://orcid.org/0000-0001-5346-6451)
- Takahiro Suzuki (ORCID: https://orcid.org/0009-0008-3086-4666)
- Shun Yamamoto (ORCID: https://orcid.org/0000-0002-0895-5667)
- Yusuke Nishimura (ORCID: https://orcid.org/0000-0001-9689-0586)
Institutions
- Nagoya City University (JP)
- Nagoya Central Hospital (JP)
- Nagoya Medical Center (JP)
- Nagoya University (JP)
Publication Details
- Journal
- Heliyon
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1016/j.heliyon.2024.e40190
- Citations
- 7
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.70